Fleishman partners up with clinical trial development firm

ST. LOUIS: Fleishman-Hillard has strengthened its clinical-trials practice by forming a strategic alliance with PRA International, a global clinical-trial development company.

ST. LOUIS: Fleishman-Hillard has strengthened its clinical-trials practice by forming a strategic alliance with PRA International, a global clinical-trial development company.

"It allows us to work together to pursue opportunities and [for us] to provide patient recruitment services for them," said John McAnulty; SVP and partner of Fleishman's clinical-trials division. "If PRA has an opportunity for a [potential] client and needs significant recruitment strategy, [we can] provide that as part of that offering."

McAnulty said this allows Fleishman to get on the ground floor and participate in the process earlier. The partnership makes Fleishman PRA's first selection if it's needed.

In the past, McAnulty said PRA primarily developed its own strategies.

"They're seeing our ability to offer some new and innovative strategies in addition to what they normally might offer," McAnulty said, calling it a value-add to PRA's core competency.

He added that though the two organizations had been working together for some time, they needed to formalize a business arrangement so that future collaborations could proceed with a structured approach.

Fleishman's clinical trials division provides services such as patient recruitment and retention, clinical consulting services, interactive communications, prequalification call centers, and measurement. The division has offices in Kansas City, San Francisco, Boston, Cleveland, Toronto, Frankfurt, London, Hong Kong, and Research Triangle Park, NC.

PRA has 2,500 employees and provides clinical research services to the pharmaceutical and biotechnology industries.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.